Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
6 reports, 4 independent
Updated Sep 8
Gone quiet
- Reports
- 6
- Developments
- 3
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Novo Nordisk launches Foundayo oral GLP1 to compete with Eli Lilly's Mounjaro.1 source
Companies launched oral GLP-1 drugs this year.1 source
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.Sub-event
Keep exploring
Part of
Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.Also in this story
- Market projections show the weight loss drug market is expected to reach $150 billion by 2035, driven by competition among major pharmaceutical companies.
- Eli Lilly and Novo Nordisk faced market pressure from federal policy, while the CalRx program funded Civica for production runs.
- Eli Lilly reported compliance status to HRSA and is scheduled to present data at a meeting in Stockholm.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Eli Lilly referred entities to the FDA regarding the GLP-1 market on August 24, 2026.
- Viking Therapeutics' GLP-1 results are showing how they stack up against the market leaders, Novo Nordisk and Eli Lilly.
- Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
- Eli Lilly, Merck, and Novo Nordisk are competing in the GLP-1 economics market, with Novo Nordisk referencing a SUSE cardiovascular trial.